Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0001507650-26-000009

Co-Chief Executive Officer acquired 500,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Zanganeh Mahkam · Co-Chief Executive Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-11-16 Exercise or conversion : show line 1 in the form +500,000 $1.06 $530,000 531,000 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-11-16 Exercise or conversion : show line 2 in the form Stock Option (right to buy) −500,000 800,000 D
Loading xslF345X06/wk-form4_1794878629.xml…